Suntrust Banks’s Novavax NVAX Stock Holding History

Suntrust Banks’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,604	Closed	-$70K	–	1295
2018 Q2	$70K	Sell	2,604 -1,242	-32%	-$42K	﹤0.01%	1291
2018 Q1	$162K	Buy	+3,846	New	+$155K	﹤0.01%	1231
2016 Q3	–	Sell	-2,230	Closed	-$324K	–	1570
2016 Q2	$324K	Buy	2,230 +120	+6%	+$13.8K	﹤0.01%	1133
2016 Q1	$217K	Hold	2,110	–	–	﹤0.01%	1306
2015 Q4	$353K	Buy	+2,110	New	+$325K	﹤0.01%	1059
2014 Q2	–	Sell	-796	Closed	-$72K	–	1594
2014 Q1	$72K	Hold	796	–	–	﹤0.01%	1865
2013 Q4	$81K	Buy	796 +215	+37%	+$15.2K	﹤0.01%	1793
2013 Q3	$36K	Buy	581 +16	+3%	+$901	﹤0.01%	1803
2013 Q2	$23K	Buy	+565	New	+$24.5K	﹤0.01%	1703

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Suntrust Banks's NVAX Position: Q3 2018 in Review

Suntrust Banks sold out of Novavax (NVAX) in Q3 2018, closing a stake of 2,604 shares — an estimated $70K sold.

Suntrust Banks first reported a position in NVAX in Q2 2013 and held it in 9 quarters. The position peaked at $353K in Q4 2015. 160 funds tracked by Wall St. Rank hold NVAX as of Q3 2018.

Suntrust Banks reported no remaining Novavax position as of Q3 2018 after selling out during the quarter.
Suntrust Banks sold 2,604 Novavax shares in Q3 2018, an estimated $70K.
Suntrust Banks first reported a position in Novavax in Q2 2013 and held it in 9 quarters.
Suntrust Banks's Novavax position peaked at $353K in Q4 2015.
160 funds tracked by Wall St. Rank held Novavax as of Q3 2018.

Based on Suntrust Banks's 13F filing for Q3 2018, filed 14 Nov 2018.